Sorafenib
sorafenib · Nexavar · BAY 43-9006 · SORAFENIB-D3 · 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide · N-[4-Chloro-3-(trifluoromethyl)phenyl]-({4-[2-(N-methyl-carbamoyl)(4-pyridyloxy)]phenyl}amino)-carboxamide · Sorafenib Free Base · Sorafenib free base for research
식별자 및 물리적 특성
| CAS No. | 284461-73-0 |
|---|---|
| 분자식 | C21H16ClF3N4O3 |
| 평균 분자량 | 464.8 g/mol |
| 단동위원소 질량 | 464.08630271 g/mol |
| SMILES | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1 |
| InChIKey | MLDQJTXFUGDVEO-UHFFFAOYSA-N |
| PubChem CID | 216239 |
| ChEMBL | CHEMBL1336 |
| ChEBI | CHEBI:50924 |
| EC No. | 608-209-4 |
| DTXSID | DTXSID7041128 |
화학 및 물리적 성질
| XLogP | 4.1 |
|---|---|
| 극성 표면적 | 92.4 |
| 수소 결합 공여자 수 | 3 |
| 수소 결합 수용자 수 | 7 |
| 회전 가능 결합 수 | 5 |
| 무거운 원자 수 | 32 |
| 형식 전하 | 0 |
| 복잡도 | 646 |
| PFAS | PFAS -> PFAS identified in REACH Regulation EC No. 1272/2008PFAS -> Suspected persistent, mobile, toxic (PMT) PFAS or PFAS-like compounds |
| 의약품 | Pharmaceuticals -> Antineoplastic and immunomodulating agents -> Antineoplastic agentsPharmaceuticals -> Listed in ZINC15 |
| LogP(분배 계수) | 3.8 |
| Color/Form | White solid |
| 용해도 | < 0.01 g/L1.71e-03 g/L클로로포름 (약간 용해됨), DMSO (약간 용해됨) |
| Human Drugs | Breast FeedingLactationAntineoplastic AgentsEnzyme InhibitorsProtein Kinase InhibitorsSignal Transduction InhibitorsTyrosine Kinase InhibitorsEMA approved medicines: Human medicine |
| Decomposition | Dangerous products of decomposition: thermal ecomposition may produce toxic gases such as carbon monoxide, carbon dioxide, and nitrogen oxides. /Sorafenib tosylate/ |
| 녹는점 | 187-226205.6 °C202-204°C |
| Physical Description | Solid |
| Stability/Shelf Life | Stable if stored as directedavoid strong oxidizing agents. /Sorafenib tosylate/ |
| Other Experimental Properties | White to yellowish or brownish solid. Practically insoluble in aqueous media, slightly soluble in ethanol and soluble in PEG 400 /Sorafenib tosylate/ |
| 끓는 점 | 523.3±50.0 °C(Predicted) |
| 밀도 | 1.454±0.06 g/cm3(Predicted) |
| 증기압 | 0Pa at 25℃ |
| 저장 조건 | Sealed in dry,Store in freezer, under -20°C |
| pKa(산도 계수) | 12.89±0.70(Predicted) |
| 물리적 상태 | 흰색 내지 회백색 고체. |
| 색상 | 흰색에서 황백색까지 |
| 용해도 | 100μg/L at 20℃ |
| InChI | InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31) |
| InChIKey | MLDQJTXFUGDVEO-UHFFFAOYSA-N |
| SMILES | C1(C(NC)=O)=NC=CC(OC2=CC=C(NC(NC3=CC=C(Cl)C(C(F)(F)F)=C3)=O)C=C2)=C1 |
| LogP(분배 계수) | 3.3 at 25℃ |
화학적 성질
Light Yellow Solid
안전 및 규제
| GHS 분류 | DangerH351 (40%): Suspected of causing cancer [Warning Carcinogenicity]P203, P260, P263, P264, P270, P273, P280, P318, P319, P391, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 5 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| 규제 정보 | Status: Active Update: 27-02-2023 https://echa.europa.eu/registration-dossier/-/registered-dossier/6884 |
| FDA 요건 | The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including sorafenib tosylate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Sorafenib tosylate/Drug Name: NexavarFDA Application No.: (NDA) 021923Active Ingredient: Sorafenib tosylateCompany: Bayer HealthcareOriginal Approval or Tentative Approval Date: December 20, 2005Chemical Type: 1 New molecular entity (NME)Review Classification: Priority review drug, orphan drug. /Sorafenib tosylate/ |
| Toxic Combustion Products | Unusual fire hazard: emits toxic fumes such as carbon monoxide, etc. /Sorafenib tosylate/ |
| Hazard Classes and Categories | Carc. 2 (40%) |
| 소화 절차 | Suitable extinguishing agents: water spray, carbon dioxide, dry chemical powder or foam Protective equipment: wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes. /Sorafenib tosylate/ |
| 보관 조건 | Store at 25 °C (77 °F)excursions permitted to 15-30 °C (59-86 °F) |
| 정리 방법 | Accidental release measures: After Inhalation: cordon off area of spillwear self-contained breathing apparatus, protective clothing and heavy rubber gloves. Measures for cleaning/collecting: absorb solutions with finely- powdered liquid-binding material (diatomite, universal binders)decontaminate surfaces and equipment by scrubbing with alcoholdispose of contaminated material /in accordance with prevailing country, federal, state and local regulations/. /Sorafenib tosylate/ |
용도
개요
Sorafenib is a small molecular inhibitor of several kinases involved in tumor angiogenesis and proliferation, including, but not limited to, Raf (IC50=12nM for Raf-1), VEGFR (IC50=90nM for VEGFR-2 and IC50=12nM for VEGFR-3), and platelet derived growth factor receptor (IC50=57nM for PDGFR-b). Specifically, sorafenib blocks tumor progression by inhibiting cellular proliferation that is dependent on activation of the MAPK pathway (Raf) and/or inhibiting tumor angiogenesis through VEGFR and/or PDGFR. While it may be effective in the treatment of a variety of tumors, the first approvable indication is for renal cell carcinoma. Overall, the drug appears to be well tolerated by the majority of patients at the 400 mg b.i.d. continuous dosing. As an inhibitor of multiple kinases vital for tumor progression, sorafenib may possess wide-spectrum antitumor properties and may emerge as an effective weapon against a variety of solid tumors.
용도
Sorafenib Tosylate (Bay 43-9006, Nexavar) is a small molecular inhibitor of VEGFR, PDGFR, c-Raf and B-Raf with IC50s of 18 nM, 10 nM, 3 nM and 15 nM, respectively.